<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>243 on FinStatInsight.com</title>
    <link>http://localhost:1313/tags/243/</link>
    <description>Recent content in 243 on FinStatInsight.com</description>
    <generator>Hugo</generator>
    <language>en-us</language>
    <lastBuildDate>Thu, 30 Nov 2023 15:01:35 +0300</lastBuildDate>
    <atom:link href="http://localhost:1313/tags/243/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>Cengild Medical Berhad Q1 2024 Revenue 11% Growth vs Preceding Quarter.</title>
      <link>http://localhost:1313/posts/cengild-medical-berhad-q1-2024-revenue-growth-vs-preceding-quarter/</link>
      <pubDate>Thu, 30 Nov 2023 15:01:35 +0300</pubDate>
      <guid>http://localhost:1313/posts/cengild-medical-berhad-q1-2024-revenue-growth-vs-preceding-quarter/</guid>
      <description>&lt;h3 id=&#34;cengild-medical-berhad-q1-2024-summary&#34;&gt;Cengild Medical Berhad Q1-2024 Summary&lt;/h3&gt;&#xA;&lt;p&gt;In the current quarter Q1-2024 concluding on September 30, 2023, &lt;strong&gt;Cengild Medical Berhad&lt;/strong&gt; achieved a revenue of RM17.60 million. This marks a notable growth of RM1.83 million, equivalent to &lt;strong&gt;11.62%&lt;/strong&gt;, when juxtaposed with the preceding quarter concluding on June 30, 2023, which reported revenue of RM15.77 million. The upswing in revenue can be primarily attributed to the heightened volume of patients, leading to an augmentation in both endoscopic procedures and surgeries conducted.&lt;/p&gt;</description>
    </item>
  </channel>
</rss>
